Moleculin Biotech, Inc. (NASDAQ:MBRX – Get Free Report) saw a significant drop in short interest during the month of May. As of May 31st, there was short interest totalling 21,100 shares, a drop of 38.3% from the May 15th total of 34,200 shares. Based on an average daily volume of 40,200 shares, the days-to-cover ratio […]
StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a report published on Wednesday morning. The brokerage issued a sell rating on the stock. A number of other research analysts also recently commented on the company. Maxim Group dropped their price objective on Moleculin Biotech from $45.00 to $20.00 and set […]
HOUSTON, May 16, 2024 /PRNewswire/ Moleculin Biotech, Inc., , a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today.
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Soft Tissue Sarcoma Pipeline, FDA Approvals, Unmet Needs, Preclinical And Discovery Stage Product, And Companies 2024 (Updated) menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.